Kornimate/medical-research-clean huggingface dataset:
effectiveness and safety of tens therapy for premature ejaculation

Conditions: Premature Ejaculation; Sex Disorder; TEN

Summary: the objective of this clinical trial is to evaluate the effectiveness and safety of transcutaneous posterior tibial nerve stimulation therapy in patients with premature ejaculation. the main question to answer is: can the effectiveness and safety of transcutaneous electrostimulation of the posterior tibial nerve alone and combined with standard pharmacological treatment be evaluated in men with lifelong premature ejaculation, compared to standard pharmacological treatment with dapoxetine? patients will: be randomized in acontrolled clinical trial. patients with a diagnosis of premature ejaculation who attend boston medical group clinics in mexico city will be included. be assigned by randomization to one of three treatment groups: * group 1: tens therapy + dapoxetine placebo on demand. * group 2: standard treatment (dapoxetine 30 mg as needed) + placebo therapy. * group 3: tens therapy + standard treatment (dapoxetine 30 mg as needed).


Eligibility criteria:
inclusion criteria: * primary premature ejaculation according to the definition of the international society for sexual medicine (issm-international society for sexual medicine) (30): a) ejaculation always or almost always occurs within the first minute after penetration, b) inability to delay ejaculation in all or almost all penetrations, c) negative personal consequences are generated, such as stress, annoyance, frustration and/or avoidance of sexual intimacy. * age between 18 and 62 years. * pedt score greater than 11. * stable heterosexual relationship for at least 6 months with interest in maintaining it for at least the duration of the study. * sexual activity at least once a week. * minimum chronicity of pd of 6 months. * voluntary participation in the study. * signing of the informed consent prior to participation in the study. exclusion criteria: * iief-ef score less than 26. * glaucoma * clinically significant comorbidity: cardiovascular, hepatic, thromboembolic, neurological, locomotor, endocrine, oncological, renal or rheumatological. * history of retroperitoneal surgery, radiotherapy or multiple sclerosis. * history of mental illness: depression, anxiety, suicidal behavior, bipolar disorder, agoraphobia, dysthymia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, psychiatric disorder, reported by the patient or due to the use of a medication for one of these conditions. * consumption of medications that affect ejaculatory control such as psychiatric medications, opioid analgesics, alpha blockers. * treatment for pe in the last 3 months. * treatment for epileptic syndromes or parkinson's disease. * use of pacemaker or cardiac defibrillator. * skin lesions in the area where the electrodes are placed. * abuse or dependence on psychoactive substances: alcohol, hallucinogenic drugs. * couple who are pregnant or interested in conceiving a pregnancy in the next 3 months.
effect of black tea extract impregnated gauze on extracted socket

Conditions: Extracted Socket

Summary: black tea is made from the leaves of a bush called camellia sinensis. the main difference between green tea and black tea is that green tea is not completely oxidized while black tea is fully oxidized. immediately after being harvested, the leaves of green tea are heated in order to halt the oxidation process, this ensures that the tea experiences minimal oxidation and stays a bright green color. black tea, meanwhile, is allowed to fully oxidize after it is harvested. this means that the leaves turn brown or black, with green no longer present anywhere on the leaf. the chemical composition of black tea are tannins, theaflavins, carbohydrates, thearubigins, protein, flavonols, mineral matter, phenolic acids, volatiles, amino acids, methylxanthine. among these, tannins play an important role in our research which helps in bleeding cessation after tooth extraction. prolonged bleeding after tooth extraction can cause discomfort and thus affect patient's healthcare. several methods have been proposed to enhance bleeding cessation, including the use of haemostatic agents and natural remedies such as tea. black tea, in particular, has been suggested to have potential haemostatic properties due to its high content of tannins and flavonoids. however, the efficacy of black tea in promoting bleeding cessation after tooth extraction remains unclear. the purpose of this study is to evaluate the effect of black tea extract on primary bleeding cessation after extraction of molars. the study aims to investigate the potential benefits of black tea in reducing the bleeding time compared to a controlled group which uses normal sterile gauze. our null hypothesis states that there is no difference in primary bleeding cessation time for black tea extract-impregnated sterile (bte) gauze and 0.5% povidone iodine-impregnated sterile (pvi) gauze. this study will be conducted in oral maxillofacial and surgery department in polyclinic a, faculty of dentistry, manipal university college malaysia (mucm). it involves forty-four randomly selected patients with molar extraction, satisfying the inclusion criteria and exclusion criteria stated. bte gauze or pvi gauze will be placed at the freshly extracted socket after extraction. the state of bleeding of the socket is observed at 2,5 and 7 minutes.


Eligibility criteria:
inclusion criteria: * age 18 years or more * asa1 (american society of anesthesiologists physical status classification 1) and asa2 patient exclusion criteria: * sensitive to black tea * using complementary medical methods (herbal medicine, etc.) within the past month * history of exposure of surgery site to radiation * using any antibiotic, corticosteroid, anticoagulant and contraceptive drug over the past month
the effects of mental fatigue created by social media on upper extremity performance

Conditions: Mental Fatigue; Upper Extremity Performance; Social Media

Summary: there are a limited number of studies in the literature, and it is stated that mental fatigue caused by social media use causes a decrease in upper-extremity movement speed and a decrease in lower-extremity endurance performance. therefore, this study aims to determine the effects of social media-induced mental fatigue on upper extremity performance.

mental fatigue is a psychobiological condition that requires prolonged cognitive activity and is characterized by subjective feelings of "tiredness" and "lack of energy." it reduces sport-related decision-making, technical skills, motor control and endurance performances. this has led to a condition known as social media fatigue among many users, where they feel exhausted from repeated exposure to an enormous amount of information from brands. social media fatigue is "the tendency of social media users to withdraw from social media when they are overwhelmed by too many social media sites, too many friends and followers, and too much time spent online to maintain these connections".researchers have drawn attention to the negative effects of internet-induced fatigue, which is increasing daily, and emphasized that excessive internet use can lead to physical and psychological problems. although there are a limited number of studies in the literature, there is a limited number of studies investigating the effects of mental fatigue caused by social media use on upper extremity performance.therefore, this study aims to determine the effects of mental fatigue caused by social media on upper extremity performance.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study * being sedentary * to be between the ages of 18-30 exclusion criteria: * any mental or sensory problems in the last six months * acute infection or chronic disease of neurological, psychiatric, orthopedic, cardiological, rheumatological, etc. origin * having had any upper extremity injury and/or operation (trauma, surgery, fracture, etc.) in the last six months * regular medication use
comparison of intravitreal bevacizumab and triamcinolone with placebo

Conditions: Acute Nonarteritic Anterior Ischemic Optic Neuropathy

Summary: in this study 16 patients diagnosed with nonarteritic anterior ischemic optic neuropathy(nsion) who had a sudden mono ocular vision loss associated with optic disc edema and positive marcus gunn in less than 30 days without exclusion criteria are randomly divided in two groups 1) control 2) case. in case group avastin and triamcinolone will be injected trough vitreal and placebo will be injected in control group. bcva and visual field will be then measured in these two groups.


Eligibility criteria:
inclusion criteria: * sudden mono ocular vision loss associated with optic disc edema and positive marcus gunn (\<30 days) exclusion criteria: * any eye disease except naion(nonarteritic anterior ischemic optic neuropathy) * neurologic defect * abnormal esr, crp, any history of retina or vitreal surgery * severe corneal opacity which makes retina examination impossible
ems prehospital blood culture collection and antibiotic administration: a two-phase pilot project to reduce mortality in patients with severe sepsis and septic shock

Conditions: Sepsis; Sepsis, Severe; Septic Shock

Summary: this study is designed to improve the outcomes for patients suffering from severe sepsis and septic shock (ss/ss) by decreasing the time from first medical contact to antibiotic administration. this is a stepwise study that aims to demonstrate the ability of paramedics to accurately obtain blood cultures prior to hospital arrival, administer a broad spectrum antibiotic and initiate iv fluid resuscitation in patients meeting predefined criteria for ss/ss.

this study is designed to improve the outcomes for patients suffering from severe sepsis and septic shock (ss/ss) by decreasing the time from first medical contact to antibiotic administration. this is a pilot project. this is a stepwise study that will build on previously published literature to demonstrate the ability of paramedics to accurately obtain blood cultures prior to hospital arrival, administer a broad spectrum antibiotic and initiate iv fluid resuscitation in patients meeting predefined criteria for ss/ss. the primary aim is to take processes that have been developed for use in this patient population during emergency department care and to advance these same processes "downrange" to initiate them prior to hospital arrival. early antibiotic administration has been shown to decrease mortality in a time dependent fashion when implemented in hospitalized patients. the investigators hypothesize that initiating antibiotics prior to hospital arrival will improve morbidity and mortality while also addressing quality metrics that are publicly reported for this patient population. this pilot study will be conducted in two consecutive phases, responding to the following aims. aim 1: evaluate the feasibility that paramedics can obtain blood cultures from general patients prior to hospital arrival with a contamination rate that is statistically equivalent to that for blood cultures obtained in emergency department. aim 2 (primary aim): investigate whether prehospital paramedic initiated broad spectrum antibiotics, administered after blood cultures are obtained, will result in improved mortality rates for patients, when compared to historical controls.

Eligibility criteria:
inclusion criteria: phase 1 (blood culture contamination rate quantification phase) 1. hemodynamically stable patients ≥18 years old being transported by lakeview ems to lakeview hospital who will have an intravenous access established as part of their routine prehospital care are eligible for this study. 2. english speaker phase 2 (blood cultures + antibiotics prehospital) a. patients with fever \>38oc + ≥2 qsofa who are being transported to lakeview hospital that originate as a 911 call exclusion criteria: phase 1: 1. patients age \<18 years 2. hemodynamic instability 3. prisoners phase 2: 1. documented allergy to penicillin or inability to determine patient's medication allergies 2. prisoners 3. pregnant patients 4. patients being transferred from one hospital to another 5. non-english speakers
clinical study of da-002 and da-005 as a treatment for hair loss

Conditions: Androgenetic Alopecia; Female Pattern Baldness; Male Pattern Baldness

Summary: the primary objective of the study is to assess the safety and efficacy of da-005 and da-002 as a treatment for hair loss (androgenetic alopecia).

da-005 is a botanical supplement with demonstrated hif-1a inhibitory action. the ingredients were tested in-vitro and have demonstrated the hif-1a inhibitory effect. the primary aim of the study is to compare da-005 to topical minoxidil in the treatment of hair loss (also known as androgenetic alopecia). da-002 is a topical alpha 1 agonist. the ingredients were tested in-vitro and have demonstrated hair growth effects. the secondary aim of the study is to compare da-002 to topical minoxidil in the treatment of hair loss (also known as androgenetic alopecia).

Eligibility criteria:
inclusion criteria: * age 18 or older * diagnosed with androgenetic alopecia * willing and able to apply the treatment as directed, comply with study * otherwise healthy * able to give informed consent exclusion criteria: * a medical history that may interfere with study objectives * women who are pregnant, lactating, or planning to become pregnant during the study period * subjects who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc) * subjects who have known allergies to any excipient in da-002 or da-005 * subjects who are currently participating in another clinical study or have completed another clinical study with an investigational drug or device in the treatment area within 30 days prior to study treatment initiation * subjects who have used any topical prescription medications in the treatment area within 30 days prior to study treatment initiation * subjects who have had a dermatological procedure such as surgery in the treatment area within 30 days prior to study treatment initiation * subject is unable to provide consent or make the allotted clinical visits
efficacy of repetitive transcranial magnetic stimulation in adult attention deficit disorder

Conditions: Attention Deficit Disorder; ADHD

Summary: the purpose of the current open-lable study was to use low-frequency repetitive transcranial magnetic stimulation (rtms) to improve the attention deficits in a sample of adult patients suffering from attention deficit disorder. participants received 10 sessions of rtms over fz (located using the eeg 10-20 international system) and underwent assessments of their attentional capacity using the gradcpt task in an fmri scanner, before and after the intervention. other behavioral assessments of their attention symptoms have also been conducted.


Eligibility criteria:
inclusion criteria: * normal intelligence level (\>90) * diagnosis of add by a psychiatrist using the adhd-rs-iv with adult prompts exclusion criteria: * scores of 21 or more on bdi and/or bai * history of head trauma * history of a major psychological or neurological condition * presence of metal in the head * history of seizures * serious cardiovascular disease * use of medications with an impact on cognitive functions during the treatment window (patients with a constant and stable dose were included) * recent use of alcohol or substance abuse

Keywords: rtms adhd add fmri
a multicenter prospective phase ii study of modified folfirinox for 1st line treatment for advanced urachus cancer

Conditions: Urachal Cancer

Summary: this study aims to assess objective response rate of modified folfirinox in advanced urachaus cancer. patients with locally advanced, recurrent, or metastatic urachal carcinoma of bladder, urachal will be enrolled this study. modified version of folfirinox(oxaliplatin 85 mg/m 2, leucovorin 400mg/m2 , irinotecan 150mg/m2 and 5-fu 2400mg/m2) with prophylactic pegateograstim will be continued till progression, unacceptable toxicity, or till 12 cycles (24 weeks). study drugs can be administered after 12 cycles to the subjects with benefit from study medication. response evaluation will be done every 6 weeks.


Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of bladder/urachal remnant that is clinically consistent with urachal cancer. origin in the anterior wall or dome of the bladder predominant invasion of muscularis or deeper tissues no obvious origin from the overlying urothelium (relative normal-looking urothelial mucosa) no primary adenocarcinoma elsewhere * patients with locally advanced, recurrent, or metastatic disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent * no prior systemic therapy for advanced urachal cancer. for recurrent disease, previous 5-fu, oxaliplatin, or irinotecan chemotherapy as neoadjuvant and/or adjuvant aim is allowed if it ended more than 6 months before enrollment. * measurable disease according to recist v1.1 criteria * ecog performance status 0 or 1 * age 19 years or older * adequate cardiac function * adequate bone marrow, hepatic, and renal function hematology * life expectancy more than 3 months * signed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment * contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. exclusion criteria: * age \> 65 * previous radiotherapy to the only measurable lesion: but previous radiotherapy will be permitted unless the lesion is the only measurable lesion * uncontrolled cns metastasis (brain and/or leptomeningeal metastasis) * grade 2 or more peripheral neuropathy * diagnosis of any serious secondary malignancy within the last 2 years, except for adequately treated basal cell or squamous cell carcinoma of skin, or in situ carcinoma of cervix uteri or prostate cancer and curatively treated thyroid cancer of any stage. * pregnancy or breast feeding, or intention of becoming pregnant during study treatment or within 6 months after final dose * other severe acute or chronic medical or psychiatric condition * chronic diarrhea * clinically significant cardiac disease (heart failure, coronary artery disease, and/or arrhythmia) * hypersensitivity to study medication * treatment with a prohibited medication or anticipation of need for prohibited medication ( section 5.5 )

Keywords: urachal cancer folfirinox
dextromethorphan and silymarin in chronic kidney disease (ckd) patients

Conditions: Proteinuria

Summary: the investigators test the renal and cardiovascular protective effects dextromethorphan and silymarin on patients with the proteinuric chronic kidney diseases, who enrolled in our clinical trial, had progressing kidney diseases and merit aggressive anti-inflammatory therapy.


Eligibility criteria:
inclusion criteria: 1. patients with stage 3 or 4 chronic kidney disease as measured by a modification in diet in renal disease study (mdrd) estimate of between 15 ml/min and 59 ml/min and and 0.5 g/day\<proteinuria\<3g/day. 2. age between 18 and 75 years old. 3. patients without hospitalization for cardiac or infection related morbidity over the previous 2 months(due to the potential confounding effects on baseline study variables). 4. patients who are able to provide consent to participate in the study.- exclusion criteria: 1. patients will significant mental illness, pregnant women, and other vulnerable populations. 2. patients with active hepatic disease and/or alt \> 2.5 times upper limit of normal. 3. patients with history of congestive heart failure and nyha class iii-iv symptoms at any time. 4. patients for whom living donor renal transplantation is already scheduled or in the process of being evaluated, as these patients will be unlikely to complete study protocols before transplantation. 5. patients with severe co-morbid conditions (eg, symptomatic hepatic cirrhosis, metastatic cancer, hiv infection with aids). 6. patient with active inflammatory process (eg., sle, rheumatoid arthritis, gout) for which they are currently receiving immune modulating medications. 7. patients who are on corticosteroid therapy. 8. patients who do not consent to participate in the study.

Keywords: ckd, proteinuria, dextromethorphan, silymarin patients with 15 ml<egfr< 60ml and 0.5 g/day<proteinuria<3g/day
long-term outcomes of post-intubation tracheal stenosis; 7-year follow-up

Conditions: Tracheal Stenosis; Intensive Care Unit

Summary: this retrospective, observational, cohort study evaluates the treatment management, long-term outcomes and survival analyses in patients hospitalized in the intensive care unit with a diagnosis of post-intubation tracheal stenosis (pits) between 1st june 2016 and 1st june 2022. the study emphasizes the role of bronchoscopic interventions in treatment management and the effective and efficient use of health services.

this retrospective study will analyze data from adult patients aged 18 years and above who were admitted with a diagnosis of post-intubation tracheal stenosis to the intensive care units of health sciences university ankara atatürk sanatorium training and research hospital and yenimahalle training and research hospital between 2016 and 2022. the analysis will examine data from both the hospital registration system and the patients' intensive care files. patients who have a history of malignancy contributing to tracheal stenosis, patients who have a history of congenital tracheal anomalies or tracheal stenosis, those with incomplete intensive care follow-up information, patient follow-up files or hospital information system data, and patients who have been repeatedly hospitalized (with only the first hospitalisation data taken into account) shall be eliminated from the study. if patients who were discharged from the intensive care unit have one-year post-discharge data, the investigators will obtain the information from the hospital's follow-up system. otherwise, investigators will collect information by calling patients or patients first-degree relatives by phone.the post-discharge data is from a past period, and the one-year follow-up period for the last patient included in the study ends on 1st june 2023. the aim of the study is to determine whether early diagnosis and interventional bronchoscopic treatment have an impact on the length of intensive care unit stay and prognosis for patients with post-intubation tracheal stenosis whilst in the intensive care unit. this will be achieved through an investigation of patient outcomes following appropriate interventions.

Eligibility criteria:
inclusion criteria: * age \> 18, * intensive care patients diagnosed with post-intubation tracheal stenosis (pits) exclusion criteria: * patients with a history of malignancy in the etiology of tracheal stenosis * patients with a history of congenital tracheal anomaly or tracheal stenosis * patients with missing intensive care follow-up form, patient follow-up file or hospital information system data * repeated hospitalizations

Keywords: tracheal stenosis post-intubation tracheal stenosis intensive care unit interventional bronchoscopy